Ltd.;Shijiazhuang Sagacity New Drug Development Co.
发明人:
WU, Lingyun,ZHANG, Peng,LI, Jian,CHEN, Shuhui
申请号：
EP17830496
公开号：
EP3492465A4
申请日:
2017.07.21
申请国别(地区):
EP
年份:
2020
代理人:
摘要：
The present invention relates to a class of tricyclic compounds and an application thereof as a sphingosine 1-phosphate type 1 (S1P1) receptor agonist. The invention specifically relates to a compound represented by formula (II), and a tautomer and pharmaceutically acceptable salt of same.
